GB2510374A - Formulation comprising N-acetylcarnitine and D-ribose - Google Patents
Formulation comprising N-acetylcarnitine and D-ribose Download PDFInfo
- Publication number
- GB2510374A GB2510374A GB1301771.0A GB201301771A GB2510374A GB 2510374 A GB2510374 A GB 2510374A GB 201301771 A GB201301771 A GB 201301771A GB 2510374 A GB2510374 A GB 2510374A
- Authority
- GB
- United Kingdom
- Prior art keywords
- formulation
- depression
- acetylcarnitine
- ribose
- chronic fatigue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000009472 formulation Methods 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 title claims abstract description 15
- 229960001009 acetylcarnitine Drugs 0.000 title claims abstract description 8
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 title claims abstract description 7
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 235000008434 ginseng Nutrition 0.000 claims abstract description 7
- 229940088594 vitamin Drugs 0.000 claims abstract description 7
- 239000011782 vitamin Substances 0.000 claims abstract description 7
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930003231 vitamin Natural products 0.000 claims abstract description 6
- 235000013343 vitamin Nutrition 0.000 claims abstract description 6
- 229940094952 green tea extract Drugs 0.000 claims abstract description 5
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 5
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 4
- 229940013317 fish oils Drugs 0.000 claims abstract description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 4
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 4
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 4
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims abstract description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960001948 caffeine Drugs 0.000 claims abstract description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims abstract description 3
- 241000208340 Araliaceae Species 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims description 13
- 206010016256 fatigue Diseases 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 238000002483 medication Methods 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
- 230000007774 longterm Effects 0.000 description 7
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- SAUDSWFPPKSVMK-LBPRGKRZSA-N (2s)-2-(n-phenylanilino)propanoic acid Chemical compound C=1C=CC=CC=1N([C@@H](C)C(O)=O)C1=CC=CC=C1 SAUDSWFPPKSVMK-LBPRGKRZSA-N 0.000 description 5
- 240000004371 Panax ginseng Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 230000003292 diminished effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 208000022119 inability to concentrate Diseases 0.000 description 2
- 230000036649 mental concentration Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000010254 physiological adaptation Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000017257 sequestering of neurotransmitter Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
 A formulation for the treatment of chronic fatigue syndrome, fibromyalgia and some depressions comprises a combination of N-acetylcarnitine and D-ribose. The formulation may also comprise: dl-phenylalanine, green tea extract, GABA, ginseng, caffeine, vitamin D3, fish oils, and multi vitamins.
Description
Description A Formulation for the treatment of chronic fatigue syndrome, chronic fatigue, fibromyalgia and depression Many patients afflicted with chronic fatigue or fibromyalgia or depression, fail to respond to conventional treatments.
A formulation comprised of N-acetylcarnitine (500 mg), D-ribose (750 mg) with further ingredients for increased therapeutic benefit including dI-phenylalanine (500mg), green tea extract (300mg standardised extract at 15% polyphenols), Korean ginseng (500mg panax ginseng at 2% ginsenosides), omega-3 fish oils (8000mg comprising 2400mg total EPA/DMA omega-3), vitamin D3 (25 micro grammes), multi-vitamins (international standard daily dose formulation) -This formulation was found very therapeutic to chronic fatigue with depression and anxiety.
This formulation was administered either as a single morning dose, or divided as a morning dose of N-acetylcarnitine, Korean ginseng and D-ribose, vitamin D3, multi vitamins (international standard formulation) and fish oils, followed by an afternoon dose of dI-phenylalanine and green tea extract.
Doses were as described above.
Alternatively for a simpler dosing regime, a complete formulation dose may be given once a day in mornings, or a complete formulation dose at half strength once in morning and once in the afternoon should afternoon fatigue be particularly problematic.
Higher total daily doses of d-ribose (up to 3g maximum) have been administered; however maximum doses of dI-phenylalanine are 500mg daily, maximum ginseng daily dose of 3g and N-acetylcarnitine maximum daily dose of 1g. To achieve these higher doses of particular ingredients without exceeding the maximum dose of other ingredients, in a single formulation, would not be possible, however the synergistic effects observed are such that the inventor finds the formulation as described above in paragraph 2, very successful. Occasional 2nd doses a day at the above doses were carried out with increased effects however the likelihood of diminished effect with long term use, cautions such continuous high dosing although this was not investigated for long periods.
A synergistic effect between N-acetylcarnitine and D-ribose was observed enabling increased physical activity, decreased fatigue, effective restoration of diminished concentration spans and effective restoration of diminished learning ability. Ginseng enhances this effect and greatly reduced fatigue especially the morning exhaustion that exacerbated late awakening. Green tea extract was also observed to reduce anxiety to some degree and dI-phenylalanine also increase concentration ability and sense of well being and reduced morning depression and intolerance to even very low levels of alcohol. VitaminD3 (25 micro grammes) was included to reduce susceptibility to infections, nerve and muscle aches and pains. Multi vitamin supplementation that included all vitamins at an international standard dose, ensured no vitamin, in particular B deficiency, was contributing to the fatigue and depression.
DI-phenylalanine is the amino-acid precursor to the important neurotransmitters dopamine, nor epinephrine and epinephrine, which may be implicated in some depressions, in particular morning depression, and inability to concentrate. Its use is contraindicated for phenyl ketonuria, Parkinson's disease, psychosis and schizophrenia.
N-acetylcarnitine is important in the biosynthesis of acetyl-CoA and the release of energy and also the biosynthesis of acetylcholine which is a neurotransmitter important in memory and learning which may become deficient in chronic fatigue patients contributing to symptoms observed.
D-ribose is an important sugar that is important for ATP synthesis, the central energy molecule in physiology which may have become depleted.
GABA has been used successively in this formulation at 500mg however should the patient be receiving anxiety medication or sleeping pills targeting GABA receptors, long term use would not be recommended in such a formulation, hence its omission in the specific formulation given in paragraph 2. Separate occasional dosing 1/7 days does enhance effects.
Low doses of caffeine (20mg) have also been used successfully in this formulation, however high doses may trigger anxiety and therefore this ingredient has been omitted from the formulation.
This formulation does not specifically address serotonin biosynthesis or deficiency which is the main target of conventional therapies for depression and which may in fact have little therapeutic impact in chronic fatigue and some depressions, when other neurotransmitters are implicated. Such serotonin intervention therapy was observed to worsen the health of the inventor.
The use of combined omega-3 supplementation may have a long term therapeutic benefit, possibly by acting to increase levels of neurotransmitter storage vesicles in the brain, enabling the depleted neurotransmitters to possibly accumulate once more and therapeutic benefit to enhance and possibly become more long term.
Long term use (3 years of treatment using the regimes described) provides continuing very effective therapy to the inventor, with a return to substantially improved mental health, restoration of cognitive abilities that include great enhancement for prolonged concentration that had severely diminished, ability to learn returned, computer programming ability restored, short term-memory greatly improved, sense of well being substantially restored, physical well being restored and greatly reduced pain observed. This was observed after 4 years of failed conventional antidepressant SSRI therapy in which the inventor was afflicted with complete loss of computer programming ability, complete inability to learn new information, severe insomnia, impotence, sterility, agitation, pain, inability to concentrate or focus, severe short -term memory problems, immense fatigue that was overwhelming, depression and many periods in which the inventor could not function at more than 5% of normal levels. Such severe side effects indicated that serotonin was not the neurotransmitter to be targeted, and by increasing this system, other neurotransmitter symptoms had become depleted. Chronic mental ill-health had thus been inadvertently established, which was successfully treated and alleviated by this formulation.
Therapeutic effects of the formulation as described occur within days and accumulate over months with careful pacing of physical and mental exertions to avoid over exertions and possible collapse in to severer fatigue and depression. Regular breaks, of 2 days in each week, from mental concentration by pursuing other relaxing physical (but not too demanding) activities where prolonged mental concentration was avoided, enabling continuous and progressively improving mental and physical health.
The inventor does not recommended discontinuations of existing pharmacological medications if they are successful, unsuccessful medications that worsen patient health could be replaced by this formulation by a graduated but reasonably swift reduction over a few days and replacement (before any collapse in health can occur) under supervision of GPs or psychiatrists or clinical psychologists, alternatively it could be used as an early short term treatment and assessed for efficacy prior to deciding the direction of medication to take.
However, long term daily and continuous use of this formulation (ie 7 days per week) is to be cautioned against simply because of the possibility of reduced efficacy from prolonged continuous use, and also dependency, although no such dependency was observed, and a recommended regime is 4/7 days per week or possibly 5/7 days dosing followed by 2 days alternative treatments that may include NADH with energy drinks. NADH can quickly lose effects after a short period of prolonged use, however short term intermittent use shows some benefit, but substantially less than the formulation. By such a regime, long term efficacy and successful treatment was observed by the inventor for 3 years with no side-effects observed.
Occasional extra doses of this formulation when severe fatigue was triggered by stress and continued mental or physical exertion was beneficial. Doses as stated at 3 times a day during early stages of treatment in severe cases, with a reduction to doses above may be required in severe cases. Continuous use of more than 5/7 days per week is advised against. The preferred dosing regime would be Monday and Tuesday, Thursday and Friday, only two consecutive days of use thereby greatly reducing any physiological adaptations which may occur to reduce efficacy with time, thereby also reducing possible side effects. Although a more complex regime, the 4/7 regime for this formulation proves successful. Some existing pharmaceuticals with daily continuous administration and many side effects could well benefit from such discontinuous dosing.
As would be standard practice, a complete list of contra-indications and possible side-effects to any of these ingredients should be sought by any patient or manufacturer and all recommendations on use adhered to. All individual ingredients have been in widespread use and studies are prevalent should further information be sought. Medical advice and supervision should be sought as considered necessary. The inventor bases his findings from remarkable improvements observed from self experimentation over three years with little if any side effects observed; however the inventor accepts no responsibility or liability what so ever for any side effects or adverse effects that may occur.
Claims (2)
- Claims 1) A formulation comprising a combination of N-acetylcarnitine and D-ribose for the treatment of chronic fatigue syndrome, chronic fatigue (where CFS criteria are not fully met), fibromyalgia, depression, depression where the patient is intolerant to conventional medications or suffers significant side-effects, depression where the patient wishes for alternative medication, and non responsive depression (where conventional anti depressants have failed to achieve remission of symptoms).
- 2) A formulation according to claim 1, in which the following eight ingredients, in any combination (none to all eight) ingredients may also be added -dI-phenylalanine, green tea extract, GABA, ginseng, fish oils, caffeine, vitamin D3 and multi vitamins.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1301771.0A GB2510374A (en) | 2013-01-31 | 2013-01-31 | Formulation comprising N-acetylcarnitine and D-ribose |
| GB1321945.6A GB2510477B (en) | 2013-01-31 | 2013-12-11 | Formulations for use in the treatment of chronic fatigue and associated conditions, etc |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1301771.0A GB2510374A (en) | 2013-01-31 | 2013-01-31 | Formulation comprising N-acetylcarnitine and D-ribose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201301771D0 GB201301771D0 (en) | 2013-03-20 |
| GB2510374A true GB2510374A (en) | 2014-08-06 |
Family
ID=47988520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1301771.0A Withdrawn GB2510374A (en) | 2013-01-31 | 2013-01-31 | Formulation comprising N-acetylcarnitine and D-ribose |
| GB1321945.6A Expired - Fee Related GB2510477B (en) | 2013-01-31 | 2013-12-11 | Formulations for use in the treatment of chronic fatigue and associated conditions, etc |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1321945.6A Expired - Fee Related GB2510477B (en) | 2013-01-31 | 2013-12-11 | Formulations for use in the treatment of chronic fatigue and associated conditions, etc |
Country Status (1)
| Country | Link |
|---|---|
| GB (2) | GB2510374A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017120731A1 (en) * | 2016-01-11 | 2017-07-20 | Shanghai Yao Yuan Biotechnology Co., Ltd. | Methods and compositions for reducing body weight |
| CN114208971B (en) * | 2021-11-29 | 2023-06-09 | 中国科学院水生生物研究所 | Application of D-ribose in feed for improving flavor and meat quality of crucian |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020022052A1 (en) * | 2000-04-06 | 2002-02-21 | Dransfield Charles William | Transdermal delivery system |
| WO2008115563A1 (en) * | 2007-03-19 | 2008-09-25 | University Of Florida Research Foundation, Inc. | Liquid nutrient composition for improving performance |
| US20100189704A1 (en) * | 2000-06-14 | 2010-07-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose |
| WO2011094491A1 (en) * | 2010-01-28 | 2011-08-04 | Max International, Llc | Compositions comprising sugar-cysteine products |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002359618A1 (en) * | 2001-12-06 | 2003-06-23 | Weller Health, Inc. | Medicinal compositions and therapeutic methods |
| US20040241256A1 (en) * | 2002-12-05 | 2004-12-02 | Seymour Ehrenpreis | Medicinal compositions & therapeutic methods |
| JP4754484B2 (en) * | 2004-03-18 | 2011-08-24 | 田辺三菱製薬株式会社 | Depressive symptom improving agent |
| US8466198B2 (en) * | 2008-09-02 | 2013-06-18 | Bruce Kneller | Compositions comprising creatine salts and methods of use thereof |
| US20130059038A1 (en) * | 2011-09-01 | 2013-03-07 | John C. Gilkey | Nutritional composition |
-
2013
- 2013-01-31 GB GB1301771.0A patent/GB2510374A/en not_active Withdrawn
- 2013-12-11 GB GB1321945.6A patent/GB2510477B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020022052A1 (en) * | 2000-04-06 | 2002-02-21 | Dransfield Charles William | Transdermal delivery system |
| US20100189704A1 (en) * | 2000-06-14 | 2010-07-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose |
| WO2008115563A1 (en) * | 2007-03-19 | 2008-09-25 | University Of Florida Research Foundation, Inc. | Liquid nutrient composition for improving performance |
| WO2011094491A1 (en) * | 2010-01-28 | 2011-08-04 | Max International, Llc | Compositions comprising sugar-cysteine products |
Non-Patent Citations (1)
| Title |
|---|
| Food and nutrients in disease management, Chapter 34, 2009, Teitelbaum, J., "Fibromyalgia and Chronic Fatigue Syndrome", pp. 557-564, ISBN: 9781420067620 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201301771D0 (en) | 2013-03-20 |
| GB2510477A (en) | 2014-08-06 |
| GB201321945D0 (en) | 2014-01-22 |
| GB2510477B (en) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8609162B2 (en) | Integrated neuromodulation system for mood enhancement of a living human subject | |
| Letterman et al. | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions | |
| Pilleri et al. | Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease | |
| Timpka et al. | Device-aided treatment strategies in advanced Parkinson's disease | |
| US20190000907A1 (en) | Compositions and methods for treating insomnia and other sleep related disorders | |
| TWI583390B (en) | Ellagitannins rich extracts composition | |
| Fabbri et al. | Off-time treatment options for Parkinson’s disease | |
| Zadikoff et al. | Safety of Levodopa‐Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving≥ 2000 mg Daily Dose of Levodopa | |
| US20230233496A1 (en) | Levodopa fractionated dose composition and use | |
| US20140105878A1 (en) | Compositions and methods for prevention and treatment of migraines | |
| GB2510374A (en) | Formulation comprising N-acetylcarnitine and D-ribose | |
| EP1742639B1 (en) | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse | |
| US20240173339A1 (en) | Cannabinoid formulation for management of depression, anxiety and ptsd, and cannabinoid formulation as a sleep aid | |
| Waters | Treatment of advanced stage patients with Parkinson's disease | |
| Isaacson et al. | Improving symptom control in early Parkinson’s disease | |
| CN114072154A (en) | Compositions of gaboxadol and lithium for treating psychotic disorders | |
| Afreen | Treatment options of Parkinson’s disease: How far we are from the cure? | |
| US20180243251A1 (en) | Composition and Method for Improving Cognitive Function | |
| US20230405005A1 (en) | Treatment of gait dysfunction in neurodegenerative disease | |
| Abyad | Cobalamin Injection: Is it Useful in Lumbosacral Diseases? | |
| US20210015779A1 (en) | Therapeutic compositions and methods | |
| US20130018061A1 (en) | Method for Improving Exercise and Recovery From Exercise | |
| Gowan et al. | Disease state management: Headache-acute, chronic and migraine-and treatment options in adults | |
| US20210161926A1 (en) | Methods for Treatment of Brain Injury and Brain Dysfunction | |
| CA3212745A1 (en) | Cannabinoid formulation for management of depression, anxiety and ptsd, and cannabinoid formulation as a sleep aid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |